微芯生物：预计2025年上半年净利润同比增长173%

Core Viewpoint - Micron Biomedical expects to achieve approximately 407 million yuan in revenue for the first half of 2025, representing a year-on-year increase of 35% [1] - The company anticipates a net profit attributable to the parent company of about 30.06 million yuan for the same period, reflecting a significant year-on-year increase of 173% [1] - The net profit after deducting non-recurring gains and losses is projected to be around 21.19 million yuan, which is a 145% year-on-year increase [1] Revenue and Profit Projections - For the second quarter of 2025, the company expects a revenue increase of 43% year-on-year and a 51% increase quarter-on-quarter [1] - The company forecasts a turnaround in net profit attributable to the parent company, indicating a recovery from previous losses [1] Product Performance - The product "Sida Benamine" has recently been included in the medical insurance for diffuse large B-cell lymphoma, contributing to increased sales [1] - The sales strategy optimization for "Sigelet Sodium" and its unique advantage in "liver disease co-management" have gained market recognition, leading to significant sales growth for both products [1]